 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- | sonrotoclax (BGB-11417) / BeiGene
Journal, IO biomarker: Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2. (Pubmed Central) - May 2, 2024
Comprehensive structure optimization led to the clinical candidate BGB-11417 (compound 12e, sonrotoclax), which exhibits strong in vitro and in vivo inhibitory activity against both WT Bcl-2 and the G101V mutant, as well as excellent selectivity over Bcl-xL without obvious cytochrome P450 inhibition. Currently, BGB-11417 is undergoing phase II/III clinical assessments as monotherapy and combination treatment.
- | Brukinsa (zanubrutinib) / BeiGene
New P2 trial, Combination therapy: MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL (clinicaltrials.gov) - Apr 16, 2024
P2, N=66, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | sonrotoclax (BGB-11417) / BeiGene
Journal: Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies. (Pubmed Central) - Jan 24, 2024
Currently, BGB-11417 is undergoing phase II/III clinical assessments as monotherapy and combination treatment. No abstract available
- || sonrotoclax (BGB-11417) / BeiGene
Enrollment closed: BGB-11417-102: Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies (clinicaltrials.gov) - Jan 18, 2024
P1, N=64, Active, not recruiting, Sponsor: BeiGene
No abstract available Recruiting --> Active, not recruiting
- |||||| sonrotoclax (BGB-11417) / BeiGene, Brukinsa (zanubrutinib) / BeiGene
Enrollment open: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 11, 2024
P3, N=640, Recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | sonrotoclax (BGB-11417) / BeiGene
Phase classification, Combination therapy, Monotherapy: BGB-11417-105: A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma (clinicaltrials.gov) - Jan 4, 2024
P1/2, N=167, Recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting Phase classification: P1b/2 --> P1/2
- || sonrotoclax (BGB-11417) / BeiGene
Phase classification, Trial completion date, Trial primary completion date, Monotherapy: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Dec 26, 2023
P1/2, N=122, Recruiting, Sponsor: BeiGene
Phase classification: P1b/2 --> P1/2 Phase classification: P2 --> P1/2
- | sonrotoclax (BGB-11417) / BeiGene
Phase classification: BGB-11417-101: Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies (clinicaltrials.gov) - Dec 14, 2023
P1, N=537, Recruiting, Sponsor: BeiGene
Phase classification: P2 --> P1/2 Phase classification: P1a/1b --> P1
- sonrotoclax (BGB-11417) / BeiGene
Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 ... (Grand Hyatt - Seaport Ballroom ABCD) - Nov 3, 2023 - Abstract #ASH2023ASH_5193;
P1b/2
The SMC has recommended 640 mg in combination with dexamethasone as the RP2D. Recruitment is ongoing for the sonrotoclax in combination with dexamethasone and carfilzomib dose-finding arms and the sonrotoclax plus dexamethasone indication expansion cohort.
- sonrotoclax (BGB-11417) / BeiGene
Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_3990;
P1a/1b
No clinical TLS were observed, indicating that TLS can be mitigated with current measures, including revised ramp-up. An exploratory 320-mg cohort is currently enrolling.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, sonrotoclax (BGB-11417) / BeiGene
BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_3629;
An exploratory 320-mg cohort is currently enrolling. We therefore aimed to investigate the prevalence and pattern of BAX -mutated CH across different hematological and non-hematological neoplasms in response to BCL2 inhibitor therapy (both venetoclax and BGB-11417)...We assessed a cohort of pts with metastatic breast cancer who received venetoclax in combination with tamoxifen (mBEP; Lok, Cancer Discover 2019), and detected BAX variants from peripheral blood samples in 5/16 (31%) pts (median age 66) after a median duration of 20 (range 13
- sonrotoclax (BGB-11417) / BeiGene, Brukinsa (zanubrutinib) / BeiGene
Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Respon... (Grand Hyatt - Grand Hall D) - Nov 3, 2023 - Abstract #ASH2023ASH_1378;
P1a/1b
Only one patient discontinued treatment and three patients had dosage reductions. No TLS was seen with either ramp-up schedule.
- |||||||||| sonrotoclax (BGB-11417) / BeiGene, Brukinsa (zanubrutinib) / BeiGene
New P3 trial: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 9, 2023
P3, N=640, Not yet recruiting, Sponsor: BeiGene
- ||| sonrotoclax (BGB-11417) / BeiGene
Enrollment open: Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenstr (clinicaltrials.gov) - Sep 21, 2023
P2, N=85, Recruiting, Sponsor: BeiGene
No TLS was seen with either ramp-up schedule. Not yet recruiting --> Recruiting
- || sonrotoclax (BGB-11417) / BeiGene
Trial completion date, Trial primary completion date: BGB-11417-101: Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies (clinicaltrials.gov) - Jul 28, 2023
P1a/1b, N=537, Recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
- |||| sonrotoclax (BGB-11417) / BeiGene
New P2 trial: Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenstr (clinicaltrials.gov) - Jul 20, 2023
P2, N=85, Not yet recruiting, Sponsor: BeiGene
- || sonrotoclax (BGB-11417) / BeiGene
Trial completion: A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417 (clinicaltrials.gov) - Jul 6, 2023
P1, N=6, Completed, Sponsor: BeiGene
Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027 Not yet recruiting --> Completed
- Emerging BCL 2 Inhibitors (LEVEL 3, GENERAL ASSEMBLY) - Jun 21, 2023 - Abstract #SOHO2023SOHO_212;
P1, P1/2,
Not yet recruiting --> Completed Among 52 patients with hematological malignancies the maximum tolerated dose (MTD) was not reached and no clinical TLS was observed.20 In this study of 22 evaluable patients with RR CLL there was an overall response rate (ORR) of 63.6% (14/22).20 A larger study of 114 patients with RR CLL evaluated lisaftoclax in combination with either the Bruton's tyrosine kinase inhibitor (BTKi) acalabrutinib or the anti CD20 monoclonal antibody rituximab (NCT04215809)...In CLL an overall response rate (ORR) to BGB-1147 of 100% as monotherapy was observed among 8 patients with RR disease.25 In 12 patients with RR MM, the ORR to BGB-1147 in combination with dexamethasone varied from 0
- BGB-11417 / BeiGene
A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2234;
P1
BGB-11417 monotherapy showed promising initial efficacy results in R/R CLL/SLL, with pts achieving responses at lower dose levels. Lymphoma, Chronic lymphocytic leukemia, BCL2, Hematological malignancy
- || sonrotoclax (BGB-11417) / BeiGene
New P1 trial: A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417 (clinicaltrials.gov) - May 6, 2023
P1, N=6, Not yet recruiting, Sponsor: BeiGene
- BGB-11417 / BeiGene
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies. (On Demand | Hall A; Poster Bd # 109) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3964;
P1
BGB-11417 monotherapy showed promising initial efficacy results in R/R CLL/SLL, with pts achieving responses at lower dose levels. Clinical trial information: NCT04883957.
- Venclexta (venetoclax) / Roche, AbbVie, BGB-11417 / BeiGene
BCL2 Family Inhibitors (Auditorium; Virtual) - Apr 25, 2023 - Abstract #MDS2023MDS_119;
In this non-randomized Phase 1 study, patients received AZA x 5 days and VEN x 7-14 days with an ORR of 87%.(3) The Phase III randomized and placebo-controlled VERONA study is the pivotal ongoing study to confirm a benefit in response rate and overall survival, as well as quality of life and improvements in transfusion requirements, with the combination of HMA + BCL2 inhibition as compared to azacitidine alone. Other potent BCL2 inhibitors are also under clinical development, in combination with HMA therapy for AML and high-risk MDS, including the BCL2 inhibitor BGB-11417, with updated results of these and other studies provided at the meeting as available.
- ||| BGB-11417 / BeiGene
Clinical: BGB-11417 Shows Encouraging Early Efficacy and Tolerability in CLL https://t.co/8ImGwZwJCT via @onclive issued January 2023 (Twitter) - Apr 10, 2023
- || sonrotoclax (BGB-11417) / BeiGene
Trial completion date, Trial primary completion date: BGB-11417-101: Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies (clinicaltrials.gov) - Feb 8, 2023
P1a/1b, N=506, Recruiting, Sponsor: BeiGene
Other potent BCL2 inhibitors are also under clinical development, in combination with HMA therapy for AML and high-risk MDS, including the BCL2 inhibitor BGB-11417, with updated results of these and other studies provided at the meeting as available. Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
- || sonrotoclax (BGB-11417) / BeiGene
Enrollment change: BGB-11417-102: Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies (clinicaltrials.gov) - Jan 19, 2023
P1, N=70, Recruiting, Sponsor: BeiGene
Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025 N=40 --> 70
- || BGB-11417 / BeiGene
Is Lisaf same as BGB-11417? (Twitter) - Dec 13, 2022
- ||||| Venclexta (venetoclax) / Roche, AbbVie, BGB-11417 / BeiGene
Clinical, P1 data, Monotherapy: CONGRESS | #ASH22 @chanyooncheah, @uwanews presented data from the first in-human phase I trial of BGB-11417. BGB-11417 is more potent and selective than venetoclax. No pts discontinued due to AEs. 33% CR rate in pts treated with BGB-11417 monotherapy. #lymsm #medicalcongress (Twitter) - Dec 12, 2022
- |||| BGB-11417 / BeiGene
VEN no longer the lone wolf... @chanyooncheah #ASH22 #CLL P1 trial novel BCL2i BGB-11417+/-ZANU for RR/TN CLL More potent than VEN, active against G101V (in vitro) N=79, 8 mono 71 combo 1 DLT, G≥3 AEs 28% of combo arm, mostly haem Clearly v active, CRs & uMRD seen, but FU short (Twitter) - Dec 12, 2022
- ||||| BGB-11417 / BeiGene
Clinical: BGB-11417 alone and in combo with zanu: early follow up but looks safe (neutropenia but not excessive and controlled with G-CSF) with early signs of efficacy #ASH22 (Twitter) - Dec 12, 2022
- BGB-11417 / BeiGene
Preliminary Safety and Efficacy Of BGB-11417, a Potent and Selective B-Cell Lymphoma 2 (BCL2) Inhibitor, in Patients (Pts) with Acute Myeloid Leukemia (AML) () - Nov 30, 2022 - Abstract #DKK2022DKK_2338;
P1b/2
Here, preliminary results for BGB-11417 + azacitidine (aza) in AML are presented... BGB-11417 + aza resulted in a majority of CR by the end of Cycle 1 and was well-tolerated in AML.
- ||||| BGB-11417 / BeiGene
Clinical: Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study - novel bcl-2 in 11;14 @MCWCancerCenter https://t.co/4U936UomTx (Twitter) - Nov 20, 2022
- ||| sonrotoclax (BGB-11417) / BeiGene
Enrollment open: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Nov 15, 2022
P2, N=72, Recruiting, Sponsor: BeiGene
BGB-11417 + aza resulted in a majority of CR by the end of Cycle 1 and was well-tolerated in AML. Not yet recruiting --> Recruiting
- ||||| Venclexta (venetoclax) / Roche, AbbVie, BGB-11417 / BeiGene
Clinical: https://t.co/Lf6Wl9yG6Q #ASH22 BGB-11417 is a highly selective Bcl-2 inhibitor with potency >10 times that of venetoclax in biochemical assays. Showed efficacy in B-cell malignancy. (Twitter) - Nov 9, 2022
- BGB-11417 / BeiGene, Brukinsa (zanubrutinib) / BeiGene
A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6015;
P1a/1b
No MTD was reached even at the highest dose level of 640 mg QD. All low-grade TEAEs and grade =3 neutropenia were manageable.
- BGB-11417 / BeiGene, Brukinsa (zanubrutinib) / BeiGene
A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data (ENMCC - 243-245) - Nov 4, 2022 - Abstract #ASH2022ASH_5373;
P1a/1b
Grade =3 neutropenia was uncommon and manageable. Efficacy is supported by the rapid reduction in ALC during ramp-up, and early response data are promising.
- BGB-11417 / BeiGene
Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4613;
P1b/2
Efficacy data are forthcoming. Recruitment is ongoing in the US, Australia, and New Zealand; the BGB-11417, dexamethasone, and carfilzomib combination arm will open in the future.
- BGB-11417 / BeiGene
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4371;
P1
These results demonstrated that BGB-11417 is effective and well tolerated at all tested doses, with no increase in AEs with increasing dose. Dose escalation is still ongoing because an MTD has not yet been reached in any dose-escalation cohort as of the data cutoff date, with patients being recruited.
- BGB-11417 / BeiGene
Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2282;
P1b/2
These results demonstrate that BGB-11417 in combination with aza was effective and generally well tolerated at the 4 dose levels tested in pts with AML, with no dose-dependent toxicities observed. Further evaluation of the 28-day regimen is underway.
- || sonrotoclax (BGB-11417) / BeiGene
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: BGB-11417-105: A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma (clinicaltrials.gov) - Nov 2, 2022
P1b/2, N=167, Recruiting, Sponsor: BeiGene
Further evaluation of the 28-day regimen is underway. Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2023 --> Nov 2026
- BGB-11417 / BeiGene, Brukinsa (zanubrutinib) / BeiGene
PHASE 1 STUDY WITH THE NEW B-CELL LYMPHOMA 2 INHIBITOR (BCL2) BGB-11417 IN MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS AFFECTED BY B-CELL LYMPHOPROLIFERATIVE DISEASES: PRELIMINARY DATA (PLENARY ROOM) - Oct 29, 2022 - Abstract #SIE2022SIE_410;
- || sonrotoclax (BGB-11417) / BeiGene
Trial completion date, Trial initiation date: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 26, 2022
P2, N=72, Not yet recruiting, Sponsor: BeiGene
Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2023 --> Nov 2026 Trial completion date: Jan 2025 --> Sep 2027 | Initiation date: Sep 2022 --> Dec 2022
- ||| sonrotoclax (BGB-11417) / BeiGene
Enrollment open, Monotherapy: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 19, 2022
P2, N=98, Recruiting, Sponsor: BeiGene
Trial completion date: Jan 2025 --> Sep 2027 | Initiation date: Sep 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- || BGB-11417 / BeiGene, Brukinsa (zanubrutinib) / BeiGene
P1 data, Clinical Trial,Phase I, Journal, Combination therapy, Monotherapy: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data. (Pubmed Central) - Sep 29, 2022
P1a/1b
Dose escalation continues as MTD has not been reached. Enrollment is ongoing; data for Waldenström macroglobulinemia and treatment-naïve CLL/SLL are forthcoming.
- BGB-11417 / BeiGene, Brukinsa (zanubrutinib) / BeiGene
A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data () - Sep 22, 2022 - Abstract #SOHO2022SOHO_545;
P1a/1b
Dose escalation continues as MTD has not been reached. Enrollment is ongoing; data for Waldenström macroglobulinemia and treatment-naïve CLL/SLL are forthcoming.
- ||| sonrotoclax (BGB-11417) / BeiGene
Enrollment change, Trial completion date, Trial primary completion date: BGB-11417-103: A Study of BGB-11417 in Participants With Myeloid Malignancies (clinicaltrials.gov) - Aug 19, 2022
P1b/2, N=260, Recruiting, Sponsor: BeiGene
Enrollment is ongoing; data for Waldenström macroglobulinemia and treatment-naïve CLL/SLL are forthcoming. N=110 --> 260 | Trial completion date: Jun 2024 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Dec 2023
- BGB-11417 / BeiGene
Novel Bcl-2 inhibitor BGB-11417 with excellent potency for both wild type Bcl-2 and G101V-mutated Bcl-2 (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_13125;
Our efforts may provide the opportunity to develop a novel Bcl-2 inhibitor which presents more benefits in CLL patients as well as other Bcl-2 mediated malignancies. BGB-11417 is currently undergoing phase1/2 clinical assessment in monotherapy or combination.
- |||| sonrotoclax (BGB-11417) / BeiGene
New P2 trial: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Jul 29, 2022
P2, N=72, Not yet recruiting, Sponsor: BeiGene
- |||| sonrotoclax (BGB-11417) / BeiGene
New P2 trial, Monotherapy: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 25, 2022
P2, N=98, Not yet recruiting, Sponsor: BeiGene
- BGB-11417 / BeiGene, Brukinsa (zanubrutinib) / BeiGene
A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES: PRELIMINARY DATA () - May 13, 2022 - Abstract #EHA2022EHA_1268;
P1a/1b
Dose escalation continues as an MTD has not yet been reached in any dose-escalation cohort. Enrollment continues, with data for Waldenström macroglobulinemia and treatment-naïve CLL/SLL cohorts forthcoming.
- BGB-11417 / BeiGene
PRELIMINARY SAFETY AND EFFICACY OF BGB-11417, A POTENT AND SELECTIVE B-CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) () - May 13, 2022 - Abstract #EHA2022EHA_877;
P1b/2
Seven of the 9 CRs were achieved by end of Cycle 1. Conclusion Preliminary results show that a 10-day regimen of BGB-11417 plus azacitidine resulted in a majority of CR observed by the end of Cycle 1 and was well tolerated in pts with AML.